Aron Erickson

This inventor holds 11 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 2 EPO patents. Top assignees: Chromadex Inc., The Queen's University of Belfast. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Aron Erickson. Retrieved from https://idiyas.com/inventor/aron-erickson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 2 (Patent Applications = 8)

Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 37(Granted Patents)

Company Filing History:

The Queen's University of Belfast

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12558367 - Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof (2026-02-24),

2. 12485134 - Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations (2025-12-02),

3. 12195494 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2025-01-14),

4. 11746123 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2023-09-05),

5. 11345720 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2022-05-31),

6. 11274117 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2022-03-15),

7. 11242364 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2022-02-08),

8. 11214589 - Crystalline forms of nicotinoyl ribosides and derivatives thereof, and methods of preparation thereof (2022-01-04),

9. 10689411 - Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof (2020-06-23),

10. 10183036 - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors (2019-01-22),

11. 9975915 - Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof (2018-05-22),

Title: Top Inventor in Longmont, Colorado

Introduction: Richard M. Fitzpatrick is a prominent inventor based in Longmont, Colorado. He has made significant contributions to his field, showcasing his innovative spirit and expertise.

Latest Patents: Richard has recently been awarded several patents that highlight his inventive capabilities and commitment to advancing technology.

Career Highlights: Throughout his career, Richard has achieved numerous milestones, establishing himself as a leader in his industry.

Collaborations: He has worked with various organizations and individuals, fostering partnerships that enhance his projects and broaden his impact.

Conclusion: Richard M. Fitzpatrick continues to inspire with his work, leaving a lasting legacy in the world of innovation.

Profile summary based on public USPTO records.